 |
|
|
| |
Healthcare Staff Perspectives on the Implementation of HIV Injectable Treatment: Interim Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL)
|
| |
| |
EACS 2021 Oct 27-30
Cassidy Gutner1, Rebecca DeMoor2, Susan Tomkins2, Martin Gill2, Samia Dakhia3, Melanie Schroeder3, Michelle Moorhouse4, Nicola Barnes5, Savita Bakhshi Anand5, Emma L. Low5, Laurent Hocqueloux6, Francisco Jesús Vera Mendez7, Celia Jonsson Oldenbuettel8, Berend J. van Welzen9, Stéphane De Wit10, Matthew Bosse1, Maggie Czarnogorski1
1ViiV Healthcare, Research Triangle Park, NC, United States; 2GlaxoSmithKline, Brentford, United Kingdom; 3ViiV Healthcare, Brentford, United Kingdom; 4ViiV Healthcare, Bryanston, South Africa; 5Evidera, London, United Kingdom;
6CHR d'Orléans, Hôpital de la Source, Orléans, France; 7Hospital General Universitario de Santa Lucía, Murcia, Spain; 8MUC Research GmbH, Muenchen, Germany; 9UMC Utrecht, Utrecht, the Netherlands; 10CHU Saint-Pierre, Brussels, Belgium
|
| |
|
|
|
|
|
